Literature DB >> 10944603

Decreased expression of p57(KIP2)mRNA in human bladder cancer.

M Oya1, W A Schulz.   

Abstract

To identify targets of genetic and epigenetic alterations on chromosome 11p15.5 in human bladder cancer, expression of the imprinted KIP2, IGF2 and H19 genes was studied by quantitative RT-PCR in 24 paired samples of urothelial carcinomas and morphologically normal mucosa obtained by cystectomy, and in bladder carcinoma cell lines. The most frequent alteration in tumour tissue was decreased expression of KIP2 identified in 9/24 (37%) specimens. Decreased IGF2 and H19 mRNA levels were found in five (21%) and three (13%) tumours, respectively. One tumour each overexpressed IGF2 and H19. Loss of H19 expression was only found associated with loss of KIP2 expression, whereas decreased expression of IGF2 mRNA occurred independently. Almost all bladder carcinoma cell lines showed significant changes in the expression of at least one gene with diminished expression of KIP2 mRNA as the most frequent alteration. IGF2 mRNA levels were diminished in several lines, but increased in others. The KIP2 gene could be an important target of genetic and epigenetic alterations in bladder cancer affecting the maternal chromosome 11p15.5. However, reminiscent of the situation in Wilms' tumours, expression of the IGF2 gene on the paternal chromosome can also be disturbed in bladder cancers. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10944603      PMCID: PMC2363522          DOI: 10.1054/bjoc.2000.1298

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis.

Authors:  T Tokino; T Urano; T Furuhata; M Matsushima; T Miyatsu; S Sasaki; Y Nakamura
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

2.  Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome.

Authors:  M P Lee; M DeBaun; G Randhawa; B A Reichard; S J Elledge; A P Feinberg
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

3.  Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors.

Authors:  D O'Keefe; D Dao; L Zhao; R Sanderson; D Warburton; L Weiss; K Anyane-Yeboa; B Tycko
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

4.  Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma.

Authors:  N Nonomura; K Nishimura; T Miki; N Kanno; Y Kojima; M Yokoyama; A Okuyama
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

5.  A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome.

Authors:  N J Smilinich; C D Day; G V Fitzpatrick; G M Caldwell; A C Lossie; P R Cooper; A C Smallwood; J A Joyce; P N Schofield; W Reik; R D Nicholls; R Weksberg; D J Driscoll; E R Maher; T B Shows; M J Higgins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

6.  Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors.

Authors:  I Hatada; J Inazawa; T Abe; M Nakayama; Y Kaneko; Y Jinno; N Niikawa; H Ohashi; Y Fukushima; K Iida; C Yutani; S Takahashi; Y Chiba; S Ohishi; T Mukai
Journal:  Hum Mol Genet       Date:  1996-06       Impact factor: 6.150

7.  Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis.

Authors:  K Okamoto; I M Morison; T Taniguchi; A E Reeve
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

8.  Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies.

Authors:  W A Schulz; A Krummeck; I Rösinger; P Eickelmann; C Neuhaus; T Ebert; B J Schmitz-Dräger; H Sies
Journal:  Pharmacogenetics       Date:  1997-06

9.  Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5.

Authors:  M Kondo; S Matsuoka; K Uchida; H Osada; M Nagatake; K Takagi; J W Harper; T Takahashi; S J Elledge; T Takahashi
Journal:  Oncogene       Date:  1996-03-21       Impact factor: 9.867

10.  Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines.

Authors:  M O Grimm; B Jürgens; W A Schulz; K Decken; D Makri; B J Schmitz-Dräger
Journal:  Urol Res       Date:  1995
View more
  9 in total

1.  Effect of 5-aza-2'-deoxycytidine on Estrogen Receptor Alpha/Beta and DNA Methyltransferase 1 Genes Expression, Apoptosis Induction, and Cell Growth Prevention of the Colon Cancer HT 29 Cell Line.

Authors:  Masumeh Sanaei; Fraidoon Kavoosi
Journal:  Int J Prev Med       Date:  2020-09-10

2.  Effect of 5-aza-2'-deoxycytidine on p27Kip1, p21Cip1/Waf1/Sdi1, p57Kip2, and DNA methyltransferase 1 Genes Expression, Cell Growth Inhibition and Apoptosis Induction in Colon Cancer SW 480 and SW 948 Cell Lines.

Authors:  Masumeh Sanaei; Fraidoon Kavoosi; Sedighe Nasiri
Journal:  Galen Med J       Date:  2020-12-26

3.  Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate.

Authors:  Noa Matarasso; Anat Bar-Shira; Uri Rozovski; Serena Rosner; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

Review 4.  Cell cycle and no end.

Authors:  Mathewos Tessema; Ulrich Lehmann; Hans Kreipe
Journal:  Virchows Arch       Date:  2004-02-17       Impact factor: 4.064

5.  p57(KIP2) control of actin cytoskeleton dynamics is responsible for its mitochondrial pro-apoptotic effect.

Authors:  E Kavanagh; P Vlachos; V Emourgeon; J Rodhe; B Joseph
Journal:  Cell Death Dis       Date:  2012-05-17       Impact factor: 8.469

6.  Effect of 5-Aza-2'-Deoxycytidine in Comparison to Valproic Acid and Trichostatin A on Histone Deacetylase 1, DNA Methyltransferase 1, and CIP/KIP Family (p21, p27, and p57) Genes Expression, Cell Growth Inhibition, and Apoptosis Induction in Colon Cancer SW480 Cell Line.

Authors:  Masumeh Sanaei; Fraidoon Kavoosi
Journal:  Adv Biomed Res       Date:  2019-08-21

7.  Systems Biology Integration and Screening of Reliable Prognostic Markers to Create Synergies in the Control of Lung Cancer Patients.

Authors:  Aman Chandra Kaushik; Aamir Mehmood; Dong-Qing Wei; Xiaofeng Dai
Journal:  Front Mol Biosci       Date:  2020-04-07

8.  CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer.

Authors:  Pamela S Larson; Benjamin L Schlechter; Chia-Lin King; Qiong Yang; Chelsea N Glass; Charline Mack; Robert Pistey; Antonio de Las Morenas; Carol L Rosenberg
Journal:  BMC Cancer       Date:  2008-03-06       Impact factor: 4.430

Review 9.  Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases.

Authors:  Emanuela Stampone; Ilaria Caldarelli; Alberto Zullo; Debora Bencivenga; Francesco Paolo Mancini; Fulvio Della Ragione; Adriana Borriello
Journal:  Int J Mol Sci       Date:  2018-04-02       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.